Medical Condition News

RSS

Sangart completes enrollment for MP4OX Phase IIa study in severely injured trauma patients

Sangart, Inc., today announced that enrollment was completed in a Phase IIa clinical study of MP4OX (oxygenated pegylated hemoglobin) in severely injured trauma patients with hemorrhagic shock causing lactic acidosis. Complete study results are expected, after follow up of outcomes in these patients, in the second half of 2010.

30 Jun 2010

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

The U.S. Food & Drug Administration (FDA) has granted Investigational New Drug (IND) regulatory clearance to initiate a Phase I/II clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, based on research by Dr. Eli Lewis of Israel's Ben-Gurion University of the Negev.

30 Jun 2010

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

30 Jun 2010

Minnesota professor receives NIH grant to study effectiveness of community-based program to prevent childhood obesity

Many children in the U.S. have poor diets and in fact, 1 in 3 is overweight or obese. Parents struggle to have meals together with children and provide them with nutritious foods. They often rely on convenient and processed foods.

30 Jun 2010

Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular diseases, today announces positive safety data and preliminary efficacy results from its clinical trial of C-Cure(R), a breakthrough stem cell therapy for heart failure.

30 Jun 2010

BSP receives European CE conformance mark for HyperQ AD-100 add-on system

BSP, which develops and commercializes advanced products for the non invasive, accurate diagnosis of heart diseases, announced today that its Add-On product, the HyperQ AD-100, intended for improved diagnostic performance of Stress ECG, has been granted the European CE conformance mark.

30 Jun 2010

USPTO grants Vermillion Alzheimer's disease biomarker patent

Vermillion, Inc., a molecular diagnostics company, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance of a patent entitled "Biomarkers for Alzheimer's disease" to the Company.

29 Jun 2010

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Threshold Pharmaceuticals, Inc., today announced that it has initiated a Phase 1 clinical trial of TH-302 in patients with advanced leukemias. TH-302 is a proprietary Hypoxia-Activated Prodrug (HAP) that specifically targets tumor hypoxia.

29 Jun 2010

Siemens Radiation Reduction Alliance launched

In a continual commitment to patient care and radiation reduction in computed tomography (CT), Siemens Healthcare has launched SIERRA (Siemens Radiation Reduction Alliance) and has established an expert panel to advance the cause of dose reduction in CT. The new Low Dose Expert Panel includes 15 specialists in radiology, cardiology and physics, who are internationally recognized for their publications on the subject of CT dose.

29 Jun 2010

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its applications for ALN-TTR01 have been given clearance by Portuguese, Swedish, and British regulatory authorities to begin clinical testing. The trial will begin enrolling patients shortly in a blinded, randomized, placebo-controlled, multicenter Phase I study.

29 Jun 2010

Alimera submits Iluvien NDA for DME to FDA

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Iluvien®, (flucocinolone acetonide intravitreal insert), its investigational, sustained drug delivery system releasing sub-microgram levels of fluocinolone acetonide for the treatment of diabetic macular edema (DME).

29 Jun 2010

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

For someone with a severe, incurable lung disorder such as cystic fibrosis or chronic obstructive pulmonary disease, a lung transplant may be the only chance for survival. Unfortunately, it's often not a very good chance. Matching donor lungs are rare, and many would-be recipients die waiting for the transplants that could save their lives.

29 Jun 2010

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

Chelsea Therapeutics International, Ltd. announced the initiation of Study 306, a pivotal Phase III trial evaluating the efficacy of NORTHERA™, an oral synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) associated with Parkinson's disease.

29 Jun 2010

AlphaRx regains all rights to Indaflex from Cypress Bioscience

AlphaRx, Inc. today announced that it has entered into an agreement with Cypress Bioscience, under which AlphaRx is regaining all rights to Indaflex(TM) from Cypress Bioscience, which AlphaRx had previously licensed to Proprius Pharmaceuticals, which was subsequently acquired by Cypress Bioscience.

29 Jun 2010

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it has received positive Scientific Advice from the European Medicines Agency (EMA) regarding the Phase 3 trial initiated last April for the development of its lead anticancer proprietary compound, perifosine, in refractory advanced colorectal cancer.

29 Jun 2010

Vitae earns $14M milestone payment from Boehringer Ingelheim

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.

29 Jun 2010

New tool could aid in diagnosing Alzheimer's, track disease progression

A trial of a novel radioactive compound readily and safely distinguished the brains of Alzheimer's disease patients from healthy volunteers on brain scans and opens the doors to making such imaging available beyond facilities that can manufacture their own radioactive compounds.

29 Jun 2010

Rosiglitazone therapy associated with increased risk for heart attack: Study

Eleven years after the introduction of the diabetes drug rosiglitazone, data from available clinical trials demonstrate an increased risk for heart attack associated with its use and suggest an unfavorable benefit-to-risk ratio, according to a report posted online today that will appear in the July 26 print issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

29 Jun 2010

Sedentary white women are more likely to become obese

Obesity is climbing steadily among American women and an inactive lifestyle is one risk factor. A new study finds that sedentary white women are more apt to become obese than are sedentary African-American women.

29 Jun 2010

Statins does not reduce death risk in high-risk individuals without heart disease

A meta-analysis of previously published studies finds no evidence that statins are associated with a reduced risk of death among individuals at risk for but with no history of cardiovascular disease, according to a report in the June 28 issue of Archives of Internal Medicine, one of the JAMA/Archives journals

29 Jun 2010

Medical Condition News

Sangart completes enrollment for MP4OX Phase IIa study in severely injured trauma patients

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

Minnesota professor receives NIH grant to study effectiveness of community-based program to prevent childhood obesity

Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure

BSP receives European CE conformance mark for HyperQ AD-100 add-on system

USPTO grants Vermillion Alzheimer's disease biomarker patent

Threshold Pharmaceuticals commences TH-302 Phase 1 clinical trial in patients with advanced leukemias

Siemens Radiation Reduction Alliance launched

Alnylam receives Portuguese, Swedish, British approvals to initiate ALN-TTR01 Phase I study in ATTR

Alimera submits Iluvien NDA for DME to FDA

Successful growth of mouse embryonic stem cells in rat lungs raises hopes for engineering human transplants

Chelsea initiates NORTHERA Phase III trial for symptomatic NOH associated with PD

AlphaRx regains all rights to Indaflex from Cypress Bioscience

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Vitae earns $14M milestone payment from Boehringer Ingelheim

New tool could aid in diagnosing Alzheimer's, track disease progression

Rosiglitazone therapy associated with increased risk for heart attack: Study

Sedentary white women are more likely to become obese

Statins does not reduce death risk in high-risk individuals without heart disease

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News